Our partners help equip us with the tools, information, and support needed to achieve our mission. As we continue to develop a consistent, high-quality source of primary human hepatocytes, or liver cells, and apply those cells to multiple research and clinical applications, our partners are an important part of our success. With the guidance of global leaders in research, development, and healthcare, including Mayo Clinic, Precigen Exemplar, and Children’s Minnesota, we have made strides toward a world with improved access to high-quality primary human hepatocytes.

There is a broad and deep need for a high-quality, consistent source of primary human hepatocytes, or liver cells, in the scientific community. Primary human hepatocytes are currently used to screen for adverse effects in drug development and to advance liver disease-specific research, and have been shown to effectively treat liver disease, among other applications. However, the finite supply of human hepatocytes limits research and clinical application opportunities. With more dependable, accessible, and high-quality liver cells provided by Cytotheryx, more research and development for medical breakthroughs will be possible.

Our team is developing a bio-incubator that will allow us to propagate high-quality primary human hepatocytes, or liver cells. These cells can then be used by pharmaceutical companies developing new drugs to test for toxicity and safety, the liver research community for the development of new therapeutics for liver failure, liver disease, and rare diseases, and the advancement of other, disease-specific research.